To date, the U.S. Food and Drug Administration has approved two biological drugs for SLE: the anti-B-cell-activating factor IgG belimumab (anti-BAFF) and the anti-interferon alpha-receptor 1 IgG anifrolumab (anti-IFNAR1). This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.